Abstract:The non-dystrophic myotonias are an important group of skeletal muscle channelopathies electrophysiologically characterized by altered membrane excitability. Many distinct clinical phenotypes are now recognized and range in severity from severe neonatal myotonia with respiratory compromise through to milder late-onset myotonic muscle stiffness. Specific genetic mutations in the major skeletal muscle voltage gated chloride channel gene and in the voltage gated sodium channel gene are causative in most patients. Recent work has allowed more precise correlations between the genotype and the electrophysiological and clinical phenotype. The majority of patients with myotonia have either a primary or secondary loss of membrane chloride conductance predicted to result in reduction of the resting membrane potential. Causative mutations in the sodium channel gene result in an abnormal gain of sodium channel function that may show marked temperature dependence. Despite significant advances in the clinical, genetic and molecular pathophysiological understanding of these disorders, which we review here, there are important unresolved issues we address: (i) recent work suggests that specialized clinical neurophysiology can identify channel specific patterns and aid genetic diagnosis in many cases however, it is not yet clear if such techniques can be refined to predict the causative gene in all cases or even predict the precise genotype; (ii) although clinical experience indicates these patients can have significant progressive morbidity, the detailed natural history and determinants of morbidity have not been specifically studied in a prospective fashion; (iii) some patients develop myopathy, but its frequency, severity and possible response to treatment remains undetermined, furthermore, the pathophysiogical link between ion channel dysfunction and muscle degeneration is unknown; (iv) there is currently insufficient clinical trial evidence to recommend a standard treatment. Limited data suggest that sodium channel blocking agents have some efficacy. However, establishing the effectiveness of a therapy requires completion of multi-centre randomized controlled trials employing accurate outcome measures including reliable quantitation of myotonia. More specific pharmacological approaches are required and could include those which might preferentially reduce persistent muscle sodium currents or enhance the conductance of mutant chloride channels. Alternative strategies may be directed at preventing premature mutant channel degradation or correcting the mis-targeting of the mutant channels.

Clinical and molecular characterization of myotonia congenita using whole-exome sequencing in Egyptian patients

Clinical analysis and gene mutation screening of CLCN1 in two myotonia congenita families

Novel chloride channel gene mutations in two unrelated Chinese families with myotonia congenita.

Clinical and molecular characteristics of myotonia congenita in China: Case series and a literature review

Clinical and genetic characteristics of myotonia congenita in Chinese population

Myotonia Congenita: Clinical Characteristic and Mutation Spectrum of CLCN1 in Chinese Patients

Myotonia congenita in a Greek cohort: Genotype spectrum and impact of the CLCN1:c.501C > G variant as a genetic modifier

Clinical and Genetic Spectrum of Patients With Mitochondrial Disease in a Pediatric Egyptian Cohort: Novel Variants and Phenotypic Expansion

Genetic blueprint of congenital muscular dystrophies with brain malformations in Egypt: A report of 11 families

Genetic study of inherited peripheral neuropathy disease (Charcot–Marie Tooth) disease

Contractile properties and magnetic resonance imaging‐assessed fat replacement of muscles in myotonia congenita

A novel mutation of the CLCN1 gene in a cat with myotonia congenita: Diagnosis and treatment

Myotonic Disorders in Childhood: Diagnosis and Treatment

Special electromyographic features in a child with paramyotonia congenita: A case report and review of literature

The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment

Electromyographic Features in a Chinese Cohort with Hereditary Skeletal Muscle Channelopathies.

The diagnosis and treatment of myotonic disorders

Reporting a rare form of myopathy, myopathy with extrapyramidal signs, in an Iranian family using next generation sequencing: a case report

MLPA analysis for molecular diagnosis of spinal muscular atrophy and correlation of 5q13.2 genes with disease phenotype in Egyptian patients

New Classification and Treatment for Myotonic Disorders

Expanding the genetic spectrum of mitochondrial diseases in Tunisia: novel variants revealed by whole-exome sequencing